glp-1 mcas Not all GLP-1s work the same way for MCAS. Most patients do better on Tirzepatide, the dual incretin with both and GIP receptor agonists. But some mast cells just respond better A newly published case series

Components elute at different retention times and are commonly detected by UV absorbance

May have some wear or writing/highlighting

As with any pharmacological therapy, it is important that GLP-1 and GIP therapy is given to those who are most likely to benefit

The outcomes: Approved on first submission: 34% (286 requests) Denied, then approved on appeal with additional documentation: 29% (244 requests) Denied, appeal denied, patient switched to compounded semaglutide: 31% (260 requests) Denied, patient abandoned treatment: 6% (50 requests) The pattern that emerges: patients who succeed in getting Wegovy covered through Express Scripts are patients whose providers submitted complete documentation on the first attempt